Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207


Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans.

Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, Satyamurthy N, Small GW, Barrio JR, Huang SC.

J Nucl Med. 2010 Feb;51(2):210-8. doi: 10.2967/jnumed.109.063701. Epub 2010 Jan 15.


Automated movement correction for dynamic PET/CT images: evaluation with phantom and patient data.

Ye H, Wong KP, Wardak M, Dahlbom M, Kepe V, Barrio JR, Nelson LD, Small GW, Huang SC.

PLoS One. 2014 Aug 11;9(8):e103745. doi: 10.1371/journal.pone.0103745. eCollection 2014.


Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.


Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations.

Wong KP, Kepe V, Dahlbom M, Satyamurthy N, Small GW, Barrio JR, Huang SC.

Neuroimage. 2012 Mar;60(1):241-51. doi: 10.1016/j.neuroimage.2011.12.014. Epub 2011 Dec 16.


Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.


FDDNP binding using MR derived cortical surface maps.

Protas HD, Huang SC, Kepe V, Hayashi K, Klunder A, Braskie MN, Ercoli L, Bookheimer S, Thompson PM, Small GW, Barrio JR.

Neuroimage. 2010 Jan 1;49(1):240-8. doi: 10.1016/j.neuroimage.2009.08.035. Epub 2009 Aug 22.


Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region.

Wong KP, Wardak M, Shao W, Dahlbom M, Kepe V, Liu J, Satyamurthy N, Small GW, Barrio JR, Huang SC.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):575-88. doi: 10.1007/s00259-009-1293-8. Epub 2009 Oct 31.


Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease.

Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, Karch R, Stanek J, Wolf T, Müller M, Langer O.

Mol Imaging Biol. 2009 Jul-Aug;11(4):236-40. doi: 10.1007/s11307-009-0198-z. Epub 2009 Feb 13.


In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ.

J Nucl Med. 2010 Jun;51(6):913-20. doi: 10.2967/jnumed.109.069088. Erratum in: J Nucl Med. 2010 Aug;51(8):1327.


PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.


Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.


Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.

Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Feb;50(2):191-7. doi: 10.2967/jnumed.108.056499. Epub 2009 Jan 21.


Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

Jonasson M, Wall A, Chiotis K, Saint-Aubert L, Wilking H, Sprycha M, Borg B, Thibblin A, Eriksson J, Sörensen J, Antoni G, Nordberg A, Lubberink M.

J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.


Motion artifact reduction on parametric PET images of neuroreceptor binding.

Herzog H, Tellmann L, Fulton R, Stangier I, Rota Kops E, Bente K, Boy C, Hurlemann R, Pietrzyk U.

J Nucl Med. 2005 Jun;46(6):1059-65.


Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.

Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, Mathis CA, Dannals R, Wong DF.

Neuroimage. 2007 Jun;36(2):298-312. Epub 2007 Mar 16.


Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC.

J Nucl Med. 2005 Dec;46(12):1959-72.


Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease.

Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM.

Neurobiol Aging. 2010 Oct;31(10):1669-78. doi: 10.1016/j.neurobiolaging.2008.09.012. Epub 2008 Nov 11.


Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, Small GW.

Arch Neurol. 2011 Jun;68(6):768-74. doi: 10.1001/archneurol.2011.104.


Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):990-1000. doi: 10.1007/s00259-012-2102-3. Epub 2012 Mar 23.


Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET.

Protas HD, Kepe V, Hayashi KM, Klunder AD, Braskie MN, Ercoli L, Siddarth P, Bookheimer SY, Thompson PM, Small GW, Barrio JR, Huang SC.

Neuroimage. 2012 Jul 16;61(4):749-60. doi: 10.1016/j.neuroimage.2012.02.056. Epub 2012 Feb 28.

Supplemental Content

Support Center